» Articles » PMID: 10699961

Regulation of the Cdk Inhibitor P27 and Its Deregulation in Cancer

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2000 Mar 4
PMID 10699961
Citations 211
Authors
Affiliations
Soon will be listed here.
Abstract

p27 is a cell cycle inhibitor whose cellular abundance increases in response to many antimitogenic stimuli. In this review, we summarize the current knowledge on p27 function and its regulation by synthesis and by ubiquitin-mediated degradation. Importantly, p27 degradation is enhanced in many aggressive human tumors. The frequency with which this is observed suggests that loss of p27 may confer a growth advantage to these cancers. From a practical point of view, immunodetection of p27 in tumors may prove to be useful in the assessment of prognosis and may ultimately influence the therapy of this disease.

Citing Articles

Hypoxia-induced S-phase kinase-interacting protein 2 knockdown repressed the progression of melanoma through extracellular signal-regulated kinase 1/2 pathway.

Hu Y Cytojournal. 2025; 22:9.

PMID: 39958883 PMC: 11829309. DOI: 10.25259/Cytojournal_117_2024.


p27 and Tumors: Characterization of Variants Identified in MEN4 and Breast Cancer.

Bencivenga D, Stampone E, Azhar J, Parente D, Ali W, Del Vecchio V Cells. 2025; 14(3).

PMID: 39936980 PMC: 11817124. DOI: 10.3390/cells14030188.


Apoptosis-Cell Cycle-Autophagy Molecular Mechanisms Network in Heterogeneous Aggressive Phenotype Prostate Hyperplasia Primary Cell Cultures Have a Prognostic Role.

Matei E, Enciu M, Rosu M, Voinea F, Mitroi A, Deacu M Int J Mol Sci. 2024; 25(17).

PMID: 39273277 PMC: 11394677. DOI: 10.3390/ijms25179329.


miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review.

Vo T, El-Sherbieny Abdelaal E, Jordan E, ODonovan O, McNeela E, Mehta J Biochem Biophys Rep. 2023; 37:101588.

PMID: 38088952 PMC: 10711031. DOI: 10.1016/j.bbrep.2023.101588.


Cytotoxic mechanisms of berberine-phytantriol liquid crystalline nanoparticles against non-small-cell lung cancer.

Paudel K, Manandhar B, Singh S, Gupta G, Hansbro P, Chellappan D EXCLI J. 2023; 22:516-519.

PMID: 37534226 PMC: 10390893. DOI: 10.17179/excli2023-6156.